US2013078273A1PendingUtilityA1

Vault Compositions For Immunization

62
Individually held — no corporate assignee on recordPriority: May 15, 2008Filed: Nov 26, 2012Published: Mar 28, 2013
Est. expiryMay 15, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Valerie A. KickhoeferLeonard H. RomeKathleen A. KellyCheryl I. Champion
C07K 2319/33C07K 14/295A61K 39/118C07K 2319/30A61P 31/04A61K 2039/6031A61K 2039/57C07K 14/47A61K 39/385A61K 2039/543
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for stimulating a cellular immune response in a subject, comprising administering to the subject an effective amount of an antigenic peptide or an antigenic fragment or variant thereof incorporated within a vault complex, thereby stimulating a cellular immune response. 
     
     
         2 . The method of  claim 1 , wherein the antigenic peptide is fused to INT. 
     
     
         3 . The method of  claim 1 , wherein the antigenic peptide is fused to MVP. 
     
     
         4 . The method of  claim 3 , wherein the antigenic peptide is fused to the N-terminus of MVP. 
     
     
         5 . The method of  claim 1 , wherein the vault complex comprises MVP. 
     
     
         6 . The method of  claim 5 , wherein the number of MVP is 1-78. 
     
     
         7 . The method of  claim 5 , wherein the number of MVP is 78. 
     
     
         8 . The method of  claim 5 , wherein the vault complex further comprises VPARP or modified VPARP, or a portion of VPARP, or a modified portion of VPARP. 
     
     
         9 . The method of  claim 1 , wherein the cellular immune response is induction of Th cells. 
     
     
         10 . The method of  claim 9 , wherein the Th cells comprise Th-1 cells. 
     
     
         11 . The method of  claim 1 , wherein the cellular immune response is induction of CD4 +  and/or CD8+ T-cells. 
     
     
         12 . The method of  claim 1 , wherein the cellular immune response is production of INFγ. 
     
     
         13 . A pharmaceutical composition for stimulating a cellular immune response in a subject, comprising an antigenic peptide or an antigenic fragment or variant thereof incorporated within a vault complex, and at least one pharmaceutically acceptable excipient, sufficient to stimulate a cellular immune response. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein antigenic peptide is fused to INT. 
     
     
         15 . The pharmaceutical composition of  claim 13 , wherein the antigenic peptide is fused to MVP. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the vault complex comprises MVP. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the number of MVP is 1-78. 
     
     
         18 . The pharmaceutical composition of  claim 16 , wherein the number of MVP is 78. 
     
     
         19 . The pharmaceutical composition of  claim 16 , wherein the vault complex further comprises VPARP or modified VPARP, or a portion of VPARP, or a modified portion of VPARP. 
     
     
         20 . The pharmaceutical composition of  claim 13 , wherein the cellular immune response is induction of Th cells. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein the Th cells comprise Th-1 cells. 
     
     
         22 . The pharmaceutical composition of  claim 13 , wherein the cellular immune response is induction of CD4 +  and/or CD8+ T-cells. 
     
     
         23 . The pharmaceutical composition of  claim 13 , wherein the cellular immune response is production of INFγ.

Join the waitlist — get patent alerts

Track US2013078273A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.